333 related articles for article (PubMed ID: 15723981)
1. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
Szucs TD; Holm MV; Schwenkglenks M; Zhang Z; Weintraub WS; Burnier M; Erne P
Cardiovasc Drugs Ther; 2006 Jun; 20(3):193-204. PubMed ID: 16775667
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
de Pouvourville G; Solesse A; Beillat M
Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Croom KF; Plosker GL
Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
[TBL] [Abstract][Full Text] [Related]
6. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
7. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
[TBL] [Abstract][Full Text] [Related]
8. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
Chan PS; Soto G; Jones PG; Nallamothu BK; Zhang Z; Weintraub WS; Spertus JA
Circulation; 2009 Jan; 119(3):398-407. PubMed ID: 19139382
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
10. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
11. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
12. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
O'Keefe JH; Abuissa H; Pitt B
Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
[TBL] [Abstract][Full Text] [Related]
13. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
[TBL] [Abstract][Full Text] [Related]
14. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
[TBL] [Abstract][Full Text] [Related]
15. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of captopril after myocardial infarct; comment].
Szucs T; Berger K; Schulte-Hillen J; Kleber FX
Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of eplerenone in patients with chronic heart failure.
Ademi Z; Pasupathi K; Krum H; Liew D
Am J Cardiovasc Drugs; 2014 Jun; 14(3):209-16. PubMed ID: 24610254
[TBL] [Abstract][Full Text] [Related]
18. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction Pitt B; Gheorghiade M; Zannad F; Anderson JL; van Veldhuisen DJ; Parkhomenko A; Corbalan R; Klug EQ; Mukherjee R; Solomon H;
Eur J Heart Fail; 2006 May; 8(3):295-301. PubMed ID: 16504579
[TBL] [Abstract][Full Text] [Related]
20. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]